Tamboboy, Maria Teresa C.

HRN: 15-80-75  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/29/2022
CO-AMOXICLAV 625MG (TAB)
11/29/2022
12/06/2022
PO
625mg
BID X 7 Days
Post Partum; PROM
Waiting Final Action 

Indication:  Empirical De-escalation    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: